Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

The data, e.g. on best corrected visual acuity ... brolucizumab and aflibercept for the treatment of neovascular (wet) age-related macular degeneration, shows that there is another way.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Research analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

In the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) study, currently enrolling 1200 patients, attention is focused on comparisons of bevacizumab and ranibizumab monotherapy.

Research at the Buck Institute shows that ketone bodies can best be understood ... wet age-related macular degeneration (or "wet" AMD) fail to have vision improvement with treatment, but also ...

During my visit to CES 2025, I sought out a pair of special smart glasses that could give me hope for my son's future.

Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...